Brussels, 17/08/2001 (Agence Europe) - The European Commission has approved the purchase of Du Pont Pharmaceuticals Company by Bristol-Myers Squibb Company (BMS), considering that the acquisition would only lead to a slight increase in market share for BMS and would not alter its global position.
BMS is currently the world's number five in pharmaceutical products, in which it is active, notably, in the oncology, cardiovascular and diabetes treatment sectors. Du Pont, 100% subsidiary of E.I....